Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Primary Results and Characterization of Patients with Exceptional Outcomes in a Phase 1b Study Combining PARP and MEK Inhibition, with or Without Anti-Pd-l1, for BRCA Wild-Type, Platinum-Sensitive, Recurrent Ovarian Cancer

David Mutch,Athina Voulgari, Xian (Marissa) Chen,William H. Bradley,Ana Oaknin,Jose Alejandro Perez Fidalgo,Fernando Galvez Montosa,Antonio Casado Herraez,Robert W. Holloway,Matthew A. Powell,Malgorzata Nowicka,Gabriele Schaefer,Mark Merchant,Yibing Yan

CANCER（2024）

Cited 0|Views30
Key words
immune checkpoint blockade,MEK inhibitor,MKNK1,NF1,ovarian cancer,PARP inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined